Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Melanotan II
Beginner tier: 250 mcg, daily · community consensus
Also known as: MT-II, MT-2, Melanotan 2
Roughly 80 to 90 percent of users report nausea during the first week. That number alone tells you Melanotan II (MT-II) is pharmacologically active, not a grey-market placebo. This synthetic analog of alpha-melanocyte stimulating hormone hits five melanocortin receptors at once, producing a visible tan, a noticeable libido boost, and mild appetite suppression from a single peptide. It completed Phase 1 and small Phase 2 human trials but never advanced further. Dorr and colleagues tested it in 1996 [1], and Wessells confirmed pro-erectile activity in a double-blind crossover a couple years later [2]. The loading-and-maintenance approach used today comes from community consensus, not a prescribing label.
What Is Melanotan II?
Eighty to ninety percent of people who inject this peptide feel nauseous within the first three days. That fact gets buried under tanning photos, but it matters. Melanotan II (MT-II, CAS 121062-08-6) is a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone. It binds MC1R through MC5R non-selectively, which explains both its versatility and its side-effect burden.
MC1R activation drives melanogenesis. Your skin darkens without proportional UV exposure, and the effect persists for weeks after you stop because melanin itself has a slow turnover cycle. MC4R activation produces the sexual arousal, the appetite suppression, and most of the nausea. MC3R and MC5R contribute to appetite modulation and exocrine gland effects.
The clinical data is real but thin. Dorr's 1996 Phase 1 trial [1] established tolerability and tanning response. Wessells ran a double-blind placebo-controlled crossover in men with psychogenic erectile dysfunction (n=10)[2] and confirmed erection response. No Phase 3 trial was ever conducted. No regulatory body has approved MT-II for any indication.
Community experience fills the gap. Over 500 identifiable Reddit threads across r/steroids, r/peptides, and r/malegrooming document consistent tanning outcomes within 7 to 14 days of daily loading. A 2024 British Journal of Dermatology qualitative study (n=28) captured the broader user experience, including an 8 percent rate of anxiety and panic symptoms. Five published melanoma cases, one renal infarction, and one rhabdomyolysis event sit in the literature. MT-II is a research chemical with genuine pharmacological effects and genuine risks.
How Melanotan II Works
Alpha-MSH normally binds melanocortin receptors to regulate pigmentation, appetite, and sexual arousal. MT-II mimics that signaling, but its cyclic structure and D-phenylalanine substitution make it more potent and metabolically stable than native alpha-MSH. Plasma half-life sits around 1 to 2 hours based on Dorr's Phase 1 data [1].
MC1R is the tanning receptor. When MT-II binds it, melanocytes ramp up melanin production and transfer melanin granules to surrounding keratinocytes. Skin darkens over days, not hours, because the visible effect depends on melanin distribution across the epidermis. UV exposure accelerates and deepens the result by activating melanocytes that MT-II has already primed.
MC4R handles the libido and nausea. Activation in hypothalamic circuits increases sexual arousal and erectile function; activation in the area postrema triggers the nausea that most users experience during loading. Tolerance to the nausea builds over 7 to 10 days through receptor desensitization. Appetite suppression also runs through MC4R and MC3R pathways.
MC5R contributes to exocrine gland signaling, though its clinical relevance during MT-II use is less clear. The non-selective binding profile is exactly why MT-II produces such a wide range of effects from one injection. PT-141 (bremelanotide), which was derived from MT-II, was engineered for MC4R selectivity and earned FDA approval for that reason. MT-II remains the broader, less refined tool.
Melanotan II Benefits
- Melanotan II benefits center on three pharmacological effects: UV-independent tanning, sexual function, and appetite control.
- Visible skin darkening within 7 to 14 days of daily loading, confirmed in Dorr's Phase 1 trial and reported consistently across 500+ community threads.
- Burn protection for Fitzpatrick I and II skin types. Users report that melanin deposition reduces sunburn severity during subsequent UV exposure.
- Libido and erectile enhancement, often noticed within the first week. Wessells' 1998 double-blind crossover [2] documented erection response in men with psychogenic erectile dysfunction at doses as low as 25 mcg/kg.
- Mild appetite suppression through MC3R and MC4R activation, valued by users pursuing body recomposition alongside tanning goals.
- Maintenance dosing at 250 to 500 mcg once or twice weekly sustains pigmentation for months. Melanin deposited in the skin persists 4 to 12 weeks on its own; low-frequency injections keep melanocytes active.
Melanotan II: Science vs Community Consensus
MT-II produces reliable tanning via MC1R activation and pro-erectile effects via MC4R; established in Phase 1 and small Phase 2 human trials.
Read the evidence (key study, limitations)
Never completed full clinical development. No approved dosing standard exists.
Dorr et al. 1996 Phase 1 (PMID 8637402); Wessells et al. 1998 double-blind crossover in psychogenic ED (PMID 9679884)
No Phase 3 RCTs. No regulatory submission. Maximum safe cumulative dose unknown. All dosing is extrapolated from small trials and case series. Five published melanoma cases (as of 2025). One renal infarction case (PMC7148395). One rhabdomyolysis case (PMID 23121206).
Highly effective tanner for Fitzpatrick I–II skin types; significant libido/erection enhancement.
Read the reports (what users report 5, common issues 6)
Strong nausea burden during loading limits adherence. Mole darkening causes anxiety. Sildenafil combination widely practiced but increasingly flagged as dangerous.
- Visible tan in 1–2 weeks without proportional UV exposure
- Burn protection during UV exposure (valued by Fitzpatrick I–II)
- Strong libido and erection enhancement, often within first week
- Mild appetite suppression useful for body recomposition
- Long-lasting tan; maintenance dosing sustains pigment
- Nausea in 80–90% of users during loading: most common reason for discontinuation
- Spontaneous erections: unpredictable timing, socially disruptive
- Mole darkening causes significant anxiety; some users biopsied benign lesions
- Flushing, facial redness during loading
- Anxiety/panic symptoms in a subset (~8% in 2024 BJD qualitative study)
- No quality control on research-grade sources
Science and community agree on core tanning and libido effects and general loading/maintenance structure. Diverge on dosing granularity (community uses lower starting doses than early trials), risk tolerance (community widely combines with sildenafil despite priapism signal), and maintenance rationale (community understands melanin persistence; some early trials misattributed to peptide half-life).
Melanotan II Dosage Guide
Start at 100 to 250 mcg for the first few days and inject before bed. Nausea is almost guaranteed during loading, and sleeping through it is the simplest solution. Increase by 250 mcg every 3 to 5 days only once you're tolerating the current dose.
Reconstitution math for a 10 mg vial with 2 mL bacteriostatic water: that gives you 5,000 mcg per mL, or 50 mcg per unit on a U-100 insulin syringe. So 250 mcg equals 5 units (0.05 mL), 500 mcg equals 10 units (0.10 mL), and 1,000 mcg equals 20 units (0.20 mL).
The thing most beginners miss is that UV exposure matters. MT-II primes your melanocytes, but you still need 10 to 15 minutes of sun or UV exposure during loading to activate melanin and get even pigmentation. Without it, tanning will be patchy and weighted toward areas that already have more melanocytes (face, arms, freckles).
Store lyophilized powder at 2 to 8 degrees Celsius. After reconstitution, refrigerate and use within 30 days. Never use nasal spray formulations; a 2025 case report [6] documented oral mucosal melanoma in a 22-year-old using MT-II nasally.
Prolonged continuous MC4R activation leads to receptor desensitization. Nausea and other MC4R-mediated side effects do diminish with sustained dosing (acute desensitization), but melanocyte response to MC1R may also attenuate with prolonged use. Community consensus supports loading for 2–4 weeks, transitioning to low-frequency maintenance, then cycling off entirely for 1–3 months before reloading. There is no clinical trial data directly studying cycling protocols: rationale is extrapolated from receptor pharmacology and community observation.
- Tan stops deepening despite continued loading doses
- Nausea returns after a period of tolerance (may indicate receptor re-sensitization during a break)
- Sexual effects feel reduced compared to initial loading cycle
- Anxiety or mood changes that emerged during use resolve during off-cycle
Or use the universal Peptide Calculator for any peptide.
Melanotan II Protocols by Goal
Expected: Visible tan in 7–14 days with daily UV exposure; 1–2 Fitzpatrick grade darkening by week 3
Monitor: Dermatology baseline recommended if >5 moles or Fitzpatrick I. Monitor new or changing moles monthly. Check blood pressure if combining with any vasoactive agents.
How to Use Melanotan II
- 1Clean the top of your 10 mg MT-II vial with an alcohol swab
Draw 2 mL of bacteriostatic water into a syringe and inject it slowly into the vial, aiming down the glass wall. Let it dissolve; don't shake.
- 2Step 2
This gives you a concentration of 5,000 mcg per mL, or 50 mcg per unit on a U-100 insulin syringe. For a 250 mcg dose, draw to the 5 unit mark (0.05 mL). For 500 mcg, draw to 10 units (0.10 mL).
- 3Use a 29 to 31 gauge insulin syringe, half-inch needle
Pinch a fold of skin on your abdomen or thigh and insert the needle at a 45-degree angle.
- 4Step 4
Inject slowly, then withdraw and apply light pressure with an alcohol swab. Rotate injection sites.
- 5Timing: inject before bed during the loading phase
Nausea and flushing peak 15 to 30 minutes post-injection, and sleeping through them is the easiest management strategy.
- 6During loading (days 1 through 14), inject daily
Once your tan reaches the desired level, switch to maintenance at 250 to 500 mcg, one to two times per week.
- 7Refrigerate your reconstituted vial immediately after use
Use within 30 days. If the solution appears cloudy or contains particles, discard it.
Alternative Routes
Nasal bioavailability estimated lower than SC; doses used in community (≈1–2 mg per spray) are uncontrolled and poorly characterized
A 2025 case report (PMID 40210573) documented oral mucosal malignant melanoma in a 22-year-old woman who used MT-II nasal spray. This route bypasses sterile injection but introduces uncontrolled mucosal MC1R activation. No clinical dose-response data exists for intranasal MT-II. Not recommended.
Melanotan II Stacking Protocols
Avoid
Combining MC4R agonism (pro-erectile) with PDE5 inhibition dramatically increases priapism risk. Multiple community reports of 4+ hour erections requiring emergency treatment. Five severe hypotension/syncope cases reported in 2026 Clinical Toxicology literature.
Do not combineMT-II renal infarction case (PMC7148395) involved thrombotic mechanism. Anticoagulant interaction is theoretically relevant: unclear directionality. No formal interaction data. Use with caution; monitor renal function.
MT-II causes transient blood pressure changes via MC4R autonomic effects. Additive hypotension possible with antihypertensive agents, particularly at higher doses.
How much does Melanotan II cost?
Typical price
$3.35 to $4.87 per mg
Middle half of 118 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Melanotan II Side Effects
Priapism is the side effect that demands the most respect. At higher doses, MT-II can produce sustained erections lasting over 4 hours, and this is a documented medical emergency requiring intervention [3]. Combining MT-II with PDE5 inhibitors like sildenafil or tadalafil significantly increases that risk. Multiple community reports describe 4+ hour erections that ended in emergency departments. Do not combine these agents.
Nausea hits 80 to 90 percent of users during the loading phase. It peaks on days 1 through 3 and correlates directly with dose. Starting at 100 to 250 mcg and injecting before bed lets you sleep through the worst of it. Tolerance builds over 7 to 10 days through MC4R desensitization. Some users pre-treat with ondansetron 30 minutes before injection. Nausea that persists beyond the first week usually responds to a 50 percent dose reduction.
Facial flushing and warmth affect roughly 50 to 60 percent of users during loading. This is an MC4R autonomic effect, and it resolves as tolerance develops.
Mole darkening is expected from MC1R activation. Every existing pigmented lesion gets darker, and this causes justified anxiety. At least five published melanoma cases are associated with MT-II use (Hjuler et al. 2014)[4]. Most involved pre-existing risk factors, but the association is documented. Anyone with dysplastic nevi, a personal or family history of melanoma, or FAMMM syndrome should not use this peptide. Take baseline photos and compare monthly with a dermatologist.
Renal infarction through a thrombotic mechanism was reported in one case (PMC7148395) at a cumulative dose of 27 mg over 6 months. Rhabdomyolysis occurred at a single supratherapeutic dose of 6 mg, with CPK reaching 17,773 IU/L [5]. Both events are rare but medically serious.
A 2024 BJD qualitative study (n=28) found that approximately 8 percent of users experienced anxiety or panic symptoms. Spontaneous erections at unpredictable times are common during loading and can be socially disruptive.
Contraindications include melanoma history, multiple atypical moles, FAMMM syndrome, skin cancer of any type, pregnancy or breastfeeding, cardiovascular disease, uncontrolled hypertension, autoimmune skin conditions, and renal disease or coagulation disorders. If you develop a new, asymmetric, or rapidly growing mole, stop use and see a dermatologist immediately. If an erection lasts more than 4 hours, seek emergency care. If you experience muscle pain with dark urine or flank pain, go to the ER.
Common Issues & Solutions
Nausea persisting beyond week 1: reduce dose by 50%, inject only before sleep, consider ondansetron (Zofran) 30 min before injection: nausea is MC4R-mediated via area postrema; tolerance builds over 7–10 days
Tanning uneven or patchy: UV exposure is required to activate melanin; ensure 10–15 min UV concurrent with loading doses; areas with higher melanocyte density (face, existing freckles) tan faster
Erections occurring at unwanted times: dose before sleep; reduce dose to 250 mcg; consider switching to PT-141 (on-demand, shorter acting) if tanning is not the primary goal
Moles getting noticeably darker: expected from MC1R activation; take baseline photos and compare monthly with a dermatologist; any new, asymmetric, or rapidly changing lesion needs dermatology evaluation immediately
Tan fading too quickly post-loading: transition to maintenance (250–500 mcg 1–2×/week) before full discontinuation; melanin turnover takes 4–12 weeks; maintenance keeps melanocytes activated
Ask AI about this page
Ask AI for a second opinion on Melanotan II dosing and side effects
Contraindications
- Personal or family history of melanoma or atypical mole syndrome
- History of skin cancer of any type
- Pregnancy or breastfeeding
- Cardiovascular disease or uncontrolled hypertension
- Known hypersensitivity to melanocortin peptides
- Multiple dysplastic nevi or FAMMM syndrome
- Autoimmune skin conditions
Drug Interactions
- PDE5 inhibitors (sildenafil, tadalafil): combined pro-erectile effects may increase risk of priapism
- Antihypertensives: potential additive blood pressure lowering from vasodilatory effects
- Immunosuppressants: theoretical interaction due to melanocortin involvement in immune modulation
- Other melanocortin receptor agonists (PT-141/bremelanotide): overlapping receptor activation, do not combine
- Combining MC4R agonism (pro-erectile) with PDE5 inhibition dramatically increases priapism risk. Multiple community reports of 4+ hour erections requiring emergency treatment. Five severe hypotension/syncope cases reported in 2026 Clinical Toxicology literature.
- Anticoagulants (warfarin, heparin, apixaban)
- MT-II renal infarction case (PMC7148395) involved thrombotic mechanism. Anticoagulant interaction is theoretically relevant: unclear directionality. No formal interaction data. Use with caution; monitor renal function.
Product Quality
MT-II is sold exclusively as a research chemical with zero regulatory oversight. No FDA, EMA, or TGA approval. No mandatory testing for purity, potency, or sterility. The "Barbie drug" media cycle drove mass non-research use of unverified products. Multiple case reports of adverse events may be partly attributable to impure or misdosed product. Australia moved toward Schedule 9 (prohibited substance) classification.
- A useful certificate of analysis (COA) shows HPLC purity ≥98% and mass spec confirmation
- Third-party testing carries more weight than an internal COA
- Inspect vials for particulate matter or unusual color before reconstitution
- Do not use nasal spray formulations: case report (PMID 40210573) documents oral mucosal melanoma associated with MT-II nasal spray; SC injection is the studied route
- Store lyophilized powder at 2–8°C; reconstituted solution at 2–8°C, use within 30 days
- Products with no verifiable testing history carry unknown purity and identity
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Full skin/mole exam (ABCDE criteria) | Before first use; monthly during use; 3 months post-discontinuation | No new, asymmetric, or rapidly growing lesions |
| Blood pressure | Before first dose; periodically during loading (first 2 weeks) | <140/90 mmHg at rest |
| Basic metabolic panel (BMP): creatinine, BUN | Before use if cumulative dose will exceed 10 mg; every 3 months during prolonged use | Creatinine within normal range; no unexplained rise >0.3 mg/dL from baseline |
| CPK (creatine phosphokinase) | If experiencing unexplained muscle pain or dark urine | <1,000 IU/L; CPK >10,000 = medical emergency |
MC1R activation darkens existing pigmented lesions. At least 5 published melanoma cases associated with MT-II use (most with co-risk factors). Early detection is critical.
MC4R activation affects autonomic tone; transient blood pressure changes documented
Renal infarction case (PMC7148395) occurred at 27 mg cumulative (~6 months at maintenance). Baseline renal function establishes safety threshold.
Rhabdomyolysis documented at supratherapeutic dose (6 mg single dose; CPK 17,773 IU/L: PMID 23121206)
Melanotan II Before and After
Nausea is most common during initial doses: start at 250mcg. Facial flushing and mild appetite suppression may occur. No visible tanning yet.
Skin darkening begins, especially in areas with higher melanocyte density (face, arms, existing freckles). Libido increase often noticed. Nausea typically fades.
Noticeable tan develops. Moles may darken: monitor closely. Transition to maintenance dosing (500mcg 1-2x/week). Sexual function effects stabilize.
Tan reaches desired level. Minimal UV exposure helps activate and deepen pigmentation. Maintenance dose sustains color. Side effects are generally mild or absent at this stage.
Tan fades gradually over 1-3 months as melanin turns over naturally. Sexual function effects diminish within days of stopping. No known withdrawal effects.
What to Expect
Days 1 through 3 (loading): Side effects hit hardest before any visible change. Nausea affects 80 to 90 percent of users, especially at doses above 250 mcg. Flushing, warmth, and facial redness are common. Men often experience spontaneous erections. Appetite drops. No visible tanning yet because melanin takes days to reach the skin surface. Inject before bed to sleep through the worst of it.
Days 4 through 10 (loading): Skin darkening becomes visible, starting in areas with higher melanocyte density like the face, arms, and existing freckles. Libido increases typically show up by days 5 through 7. Nausea is significantly better but not completely gone. Moles get noticeably darker, and this is where most first-timers start worrying. Expected, but monitor closely.
Weeks 2 through 4 (loading to maintenance transition): A real tan develops. Most users transition to maintenance dosing around week 2 or 3, dropping from daily injection to 250 to 500 mcg once or twice weekly. Sexual function effects level out. Side effects are minimal at maintenance doses. Mole darkening continues.
Weeks 4 through 12 (maintenance): Tan stays put with weekly or bi-weekly injections. The peptide itself clears in 1 to 2 hours, but melanin deposited in the skin lasts 4 to 12 weeks before natural cell turnover removes it. Maintenance keeps melanocytes active. Many users drop to once weekly. Some cycle off for 1 to 2 months and reload.
Post-discontinuation: The peptide clears from plasma in hours. Tan typically lasts 6 to 10 weeks. Sexual effects return to baseline within 2 to 3 days. No withdrawal symptoms have been reported. Some users note mood normalization after stopping.
Detailed Timeline: Science vs Community
MC1R activation begins melanin synthesis; MC4R drives nausea, flushing, spontaneous erections. No visible pigmentation change yet: melanin takes days to surface.
Nausea is most intense on days 1–3, especially with doses above 250 mcg. Flushing, warmth, facial redness common. Appetite suppression noticed. Most people inject before bed to sleep through it.
Melanin granules distributed to keratinocytes. Skin darkening begins in high-melanocyte areas (face, arms, freckles). MC4R adaptation reduces nausea severity.
Noticeable skin darkening, especially in sun-exposed areas. Libido increase often noticed by day 5–7. Nausea significantly better but not gone. Moles visibly darker: common source of anxiety.
Full melanin loading of skin. UV exposure now accelerates and deepens pigment. Maintenance dosing (1–2×/week) sufficient to sustain MC1R signaling as melanin turns over.
Noticeably tanned skin. Most users transitioning to maintenance around week 2–3. Sexual function effects stabilize. Side effects minimal at maintenance doses.
Melanin half-life in skin ~4–12 weeks; maintenance injections re-stimulate melanocytes to replace lost melanin. No accumulation of peptide itself (t½ ~1–2 hours).
Tan maintained with weekly or bi-weekly injections. Many users reduce to 1×/week or less. Some users cycle off for 1–2 months then reload.
Peptide clears in hours. Melanin deposited in skin persists 4–12 weeks per natural keratinocyte turnover. Libido returns to baseline within days of stopping.
Tan typically lasts 6–10 weeks. Sexual effects gone within 2–3 days of last dose. No withdrawal symptoms reported. Some users note mood normalization after stopping.
Pharmacokinetics
Source: Estimated from phase-I data (Dorr et al. 1996 PMID 8637402); cyclic structure confers t½ ~1-2h
Pharmacokinetics: Active Dose Over Time
t½ = ~1-2 hours (plasma)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Melanotan II Legal?
Melanotan II has no FDA, EMA, or TGA approval for any indication. It is sold exclusively as a research chemical. Multiple regulatory agencies have issued consumer warnings against its use, and Australia has moved toward Schedule 9 (prohibited substance) classification.
The World Anti-Doping Agency (WADA) prohibits MT-II under the S2 class (peptide hormones and growth factors). Athletes subject to anti-doping testing should not use it.
No compounding pharmacy pathway exists for MT-II. All available product is a research chemical. Quality varies widely. HPLC certificates of analysis showing purity at 98 percent or above, with mass spectrometry confirmation, are the usual benchmark. Third-party testing is the only independent check.
This content is for educational and research reference purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research compound. Peptide Schedule does not sell, distribute, or endorse the purchase of any unregulated substance.
Evidence grade: Phase 1 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Melanotan II
- Adults seeking UV-free skin tanning
- Men with psychogenic erectile dysfunction
- Individuals with low libido or sexual arousal disorders
- Fair-skinned individuals prone to sunburn (Fitzpatrick I-II)
- Researchers studying melanocortin receptor pathways
Related Peptides
What Changed for Melanotan II
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Dates to watch
- Committee review
FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.
What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.
Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations
References
- [1]Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (Dorr et al. 1996) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Synthetic melanotropic peptide initiates erections in men with psychogenic ED: double-blind, placebo controlled crossover study (Wessells et al. 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Melanotan-induced priapism: a hard-earned tan (Dreyer et al., BMJ Case Rep 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Melanoma associated with the use of melanotan-II (Hjuler et al. 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Nelson et al., Clin Toxicol 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? (Yassin Alsabbagh et al., Int J Oral Maxillofac Surg 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II (Wessells et al. 2000) (opens in a new tab)PubMed 11035391PubMed
- Discovery that a melanocortin regulates sexual functions in male and female humans (Hadley 2005) (opens in a new tab)PubMed 15996790PubMed
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization (Hadley & Dorr 2006) (opens in a new tab)PubMed 16412534PubMed
- PMC7148395 (PMC7148395) (opens in a new tab)PubMed
- PMC11664455 (PMC11664455) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Melanotan II?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 1,000s. Community mentions on Reddit: Very large volume: r/steroids, r/peptides, r/malegrooming; . Open r/melanotanII: small, ~1–2k members (opens in a new tab).
500 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.